Cargando…
Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure
Liver failure is a severe clinical syndrome with high mortality. 5-Hydroxytryptamine 3 receptor antagonists (5-HT3RAs) can reduce liver damage in animal models. We investigated whether 5-HT3RAs may improve the prognosis of liver failure. We analyzed the 28 and 90 days mortality of liver failure pati...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100675/ https://www.ncbi.nlm.nih.gov/pubmed/33967787 http://dx.doi.org/10.3389/fphar.2021.648736 |
_version_ | 1783688839318994944 |
---|---|
author | Chen, Yuting Sun, Jingkang Fan, Xiude Wang, Xiaoyun Zeng, Lu Zhang, Xiaoge Zhang, Kun Li, Na Han, Qunying Liu, Zhengwen |
author_facet | Chen, Yuting Sun, Jingkang Fan, Xiude Wang, Xiaoyun Zeng, Lu Zhang, Xiaoge Zhang, Kun Li, Na Han, Qunying Liu, Zhengwen |
author_sort | Chen, Yuting |
collection | PubMed |
description | Liver failure is a severe clinical syndrome with high mortality. 5-Hydroxytryptamine 3 receptor antagonists (5-HT3RAs) can reduce liver damage in animal models. We investigated whether 5-HT3RAs may improve the prognosis of liver failure. We analyzed the 28 and 90 days mortality of liver failure patients in relation to the use of 5-HT3RAs using data from a tertiary hospital in northwest China. According to the use of 5-HT3RAs, 419 patients with liver failure (46 acute, 93 sub-acute, 44 chronic, 236 acute on chronic) were divided into 5-HT3RA group (n = 105) and control group (n = 314). 5-HT3RAs were associated with decreased 28 days (HR 0.18, 95% CI 0.10-0.34, p < 0.001) and 90 days (HR 0.21, 95% CI 0.13-0.33, p < 0.001) mortality. After propensity score matching (PSM) (n = 67 in each group), 5-HT3RAs were still significantly associated with reduced 28 days (HR 0.10, 95%CI 0.04-0.26, p < 0.001) and 90 days (HR 0.16, 95%CI 0.08-0.31, p < 0.001) mortality. 5-HT3RA group patients had significantly higher 28 and 90 days survivals than controls both before and after PSM (all p < 0.001). This study shows that 5-HT3RAs are associated with increased survival of liver failure patients and thus may be used to treat liver failure if the findings are confirmed by additional studies. |
format | Online Article Text |
id | pubmed-8100675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81006752021-05-07 Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure Chen, Yuting Sun, Jingkang Fan, Xiude Wang, Xiaoyun Zeng, Lu Zhang, Xiaoge Zhang, Kun Li, Na Han, Qunying Liu, Zhengwen Front Pharmacol Pharmacology Liver failure is a severe clinical syndrome with high mortality. 5-Hydroxytryptamine 3 receptor antagonists (5-HT3RAs) can reduce liver damage in animal models. We investigated whether 5-HT3RAs may improve the prognosis of liver failure. We analyzed the 28 and 90 days mortality of liver failure patients in relation to the use of 5-HT3RAs using data from a tertiary hospital in northwest China. According to the use of 5-HT3RAs, 419 patients with liver failure (46 acute, 93 sub-acute, 44 chronic, 236 acute on chronic) were divided into 5-HT3RA group (n = 105) and control group (n = 314). 5-HT3RAs were associated with decreased 28 days (HR 0.18, 95% CI 0.10-0.34, p < 0.001) and 90 days (HR 0.21, 95% CI 0.13-0.33, p < 0.001) mortality. After propensity score matching (PSM) (n = 67 in each group), 5-HT3RAs were still significantly associated with reduced 28 days (HR 0.10, 95%CI 0.04-0.26, p < 0.001) and 90 days (HR 0.16, 95%CI 0.08-0.31, p < 0.001) mortality. 5-HT3RA group patients had significantly higher 28 and 90 days survivals than controls both before and after PSM (all p < 0.001). This study shows that 5-HT3RAs are associated with increased survival of liver failure patients and thus may be used to treat liver failure if the findings are confirmed by additional studies. Frontiers Media S.A. 2021-04-22 /pmc/articles/PMC8100675/ /pubmed/33967787 http://dx.doi.org/10.3389/fphar.2021.648736 Text en Copyright © 2021 Chen, Sun, Fan, Wang, Zeng, Zhang, Zhang, Li, Han and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Chen, Yuting Sun, Jingkang Fan, Xiude Wang, Xiaoyun Zeng, Lu Zhang, Xiaoge Zhang, Kun Li, Na Han, Qunying Liu, Zhengwen Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure |
title | Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure |
title_full | Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure |
title_fullStr | Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure |
title_full_unstemmed | Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure |
title_short | Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure |
title_sort | association of 5-hydroxytryptamine 3 receptor antagonists with the prognosis of liver failure |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100675/ https://www.ncbi.nlm.nih.gov/pubmed/33967787 http://dx.doi.org/10.3389/fphar.2021.648736 |
work_keys_str_mv | AT chenyuting associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure AT sunjingkang associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure AT fanxiude associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure AT wangxiaoyun associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure AT zenglu associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure AT zhangxiaoge associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure AT zhangkun associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure AT lina associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure AT hanqunying associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure AT liuzhengwen associationof5hydroxytryptamine3receptorantagonistswiththeprognosisofliverfailure |